365 related articles for article (PubMed ID: 27113227)
1. Economic Evaluation of Intravenous Immunoglobulin plus Corticosteroids for the Treatment of Steroid-Resistant Chronic Inflammatory Demyelinating Polyradiculoneuropathy in Thailand.
Bamrungsawad N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P; Dechanont S; Wu DB; Dejthevaporn C; Chaiyakunapruk N
Clin Drug Investig; 2016 Jul; 36(7):557-66. PubMed ID: 27113227
[TBL] [Abstract][Full Text] [Related]
2. Cost-utility analysis of intravenous immunoglobulin for the treatment of steroid-refractory dermatomyositis in Thailand.
Bamrungsawad N; Chaiyakunapruk N; Upakdee N; Pratoomsoot C; Sruamsiri R; Dilokthornsakul P
Pharmacoeconomics; 2015 May; 33(5):521-31. PubMed ID: 25774016
[TBL] [Abstract][Full Text] [Related]
3. A cost-effectiveness study of intravenous immunoglobulin in childhood idiopathic thrombocytopenia purpura patients with life-threatening bleeding.
Sruamsiri R; Dilokthornsakul P; Pratoomsoot C; Chaiyakunapruk N
Pharmacoeconomics; 2014 Aug; 32(8):801-13. PubMed ID: 24849397
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of intravenous immunoglobulin and prednisolone for chronic inflammatory demyelinating polyradiculoneuropathy.
McCrone P; Chisholm D; Knapp M; Hughes R; Comi G; Dalakas MC; Illa I; Kilindireas C; Nobile-Orazio E; Swan A; Van den Bergh P; Willison HJ;
Eur J Neurol; 2003 Nov; 10(6):687-94. PubMed ID: 14641514
[TBL] [Abstract][Full Text] [Related]
5. Canadian cost- utility analysis of intravenous immunoglobulin for acute childhood idiopathic thrombocytopenic purpura.
Blackhouse G; Xie F; Levine MA; Campbell K; Assasi N; Gaebel K; O'Reilly D; Tarride J; Goeree R
J Popul Ther Clin Pharmacol; 2012; 19(2):e166-78. PubMed ID: 22580389
[TBL] [Abstract][Full Text] [Related]
6. Oral fingolimod for chronic inflammatory demyelinating polyradiculoneuropathy (FORCIDP Trial): a double-blind, multicentre, randomised controlled trial.
Hughes R; Dalakas MC; Merkies I; Latov N; Léger JM; Nobile-Orazio E; Sobue G; Genge A; Cornblath D; Merschhemke M; Ervin CM; Agoropoulou C; Hartung HP;
Lancet Neurol; 2018 Aug; 17(8):689-698. PubMed ID: 30001923
[TBL] [Abstract][Full Text] [Related]
7. Results of a model analysis to estimate cost utility and value of information for intravenous immunoglobulin in Canadian adults with chronic immune thrombocytopenic purpura.
Xie F; Blackhouse G; Assasi N; Campbell K; Levin M; Bowen J; Tarride JE; Pi D; Goeree R
Clin Ther; 2009 May; 31(5):1082-91; discussion 1066-8. PubMed ID: 19539109
[TBL] [Abstract][Full Text] [Related]
8. Economic costs and quality of life in chronic inflammatory neuropathies in southeast England.
Mahdi-Rogers M; McCrone P; Hughes RA
Eur J Neurol; 2014; 21(1):34-9. PubMed ID: 23930744
[TBL] [Abstract][Full Text] [Related]
9. Utility of somatosensory evoked potentials in the assessment of response to IVIG in a long-lasting case of chronic immune sensory polyradiculopathy.
Clerici AM; Nobile-Orazio E; Mauri M; Squellati FS; Bono GG
BMC Neurol; 2017 Jul; 17(1):127. PubMed ID: 28668085
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Cost-Effectiveness of Insulin Glargine Versus Neutral Protamine Hagedorn Insulin for Type 2 Diabetes in Thailand.
Permsuwan U; Chaiyakunapruk N; Dilokthornsakul P; Thavorn K; Saokaew S
Appl Health Econ Health Policy; 2016 Jun; 14(3):281-92. PubMed ID: 26961276
[TBL] [Abstract][Full Text] [Related]
11. Steroids for chronic inflammatory demyelinating polyradiculoneuropathy: evidence base and clinical practice.
Press R; Hiew FL; Rajabally YA
Acta Neurol Scand; 2016 Apr; 133(4):228-38. PubMed ID: 26437234
[TBL] [Abstract][Full Text] [Related]
12. Clinical and economic comparison of an individualised immunoglobulin protocol vs. standard dosing for chronic inflammatory demyelinating polyneuropathy.
Rajabally YA; Afzal S
J Neurol; 2019 Feb; 266(2):461-467. PubMed ID: 30556098
[TBL] [Abstract][Full Text] [Related]
13. Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study.
RMC Trial Group
Lancet Neurol; 2009 Feb; 8(2):158-64. PubMed ID: 19136303
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of abrocitinib compared with standard of care in adult moderate-to-severe atopic dermatitis in Japan.
Tanaka A; Yuasa A; Kamei K; Nagano M; Murofushi T; Bjerke A; Nakamura K; Ikeda S
J Dermatol; 2024 Jun; 51(6):759-771. PubMed ID: 38650307
[TBL] [Abstract][Full Text] [Related]
15. Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy.
Guptill JT; Bromberg MB; Zhu L; Sharma BK; Thompson AR; Krueger A; Sanders DB
Muscle Nerve; 2014 Jul; 50(1):47-51. PubMed ID: 24639235
[TBL] [Abstract][Full Text] [Related]
16. Conventional and unconventional therapies in typical and atypical chronic inflammatory demyelinating polyneuropathy with different clinical course of progression.
Hung SKY; Hiew FL; Viswanathan S; Puvanarajah S
J Peripher Nerv Syst; 2018 Sep; 23(3):183-189. PubMed ID: 30027593
[TBL] [Abstract][Full Text] [Related]
17. Economic evaluation and budget impact analysis of the surveillance program for hepatocellular carcinoma in Thai chronic hepatitis B patients.
Sangmala P; Chaikledkaew U; Tanwandee T; Pongchareonsuk P
Asian Pac J Cancer Prev; 2014; 15(20):8993-9004. PubMed ID: 25374242
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulin response in treatment-naïve chronic inflammatory demyelinating polyradiculoneuropathy.
Kuitwaard K; Hahn AF; Vermeulen M; Venance SL; van Doorn PA
J Neurol Neurosurg Psychiatry; 2015 Dec; 86(12):1331-6. PubMed ID: 25515502
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada.
Blackhouse G; Gaebel K; Xie F; Campbell K; Assasi N; Tarride JE; O'Reilly D; Chalk C; Levine M; Goeree R
Cost Eff Resour Alloc; 2010 Jun; 8():14. PubMed ID: 20565778
[TBL] [Abstract][Full Text] [Related]
20. Cost utility analysis of reduced intensity hematopoietic stem cell transplantation in adolescence and young adult with severe thalassemia compared to hypertransfusion and iron chelation program.
Sruamsiri R; Chaiyakunapruk N; Pakakasama S; Sirireung S; Sripaiboonkij N; Bunworasate U; Hongeng S
BMC Health Serv Res; 2013 Feb; 13():45. PubMed ID: 23379888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
